Head and Neck Cancer

New Indication: Axitinib and Avelumab for Adenoid Cystic Carcinoma

2023-04-14

  • Study

    • Open-label,single-arm, phase 2 study
    Pretreated metastatic or recurrent ACC
    Axitinib + Avelumab q28 (n=28)


  • Efficacy

    ORR: 21% [8.3%-41.0%]
    mPFS: 7.3 mos [3.7-11.2 mos]
    mOS: 1.6 mos [12.4-NR]

  • Safety

    Any grade AEs: fatigue (62%), diarrhea (32%), hypertension (32%), mucositis (29%)
    Grade3 AEs: hypertension (9%), fatigue (6%), palmar-plantar erythrodysesthesia (6%)



    • J Clin Oncol 2023; 28 MAR

    Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma

    http://doi.org/10.1200/JCO.22.02221

    Reviewed by Elvin Chalabiyev, MD on Apr 14, 2023